Regeneron Pharmaceuticals Inc
REGN
View Detailed Chart
741.290USD
-5.510-0.74%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
78.06BMarket Cap
17.10P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.74%
5 Days
+3.19%
1 Month
+6.66%
6 Months
+40.07%
Year to Date
+4.07%
1 Year
+1.37%
View Detailed Chart
TradingKey Stock Score of Regeneron Pharmaceuticals Inc
Currency: USD Updated: 2025-12-12Key Insights
Regeneron Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 11/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 780.40.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regeneron Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Buy
Current Rating
780.402
Target Price
+10.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Regeneron Pharmaceuticals Inc Highlights
StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.67% year-on-year.
Fairly Valued
The company’s latest PE is 17.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.26M shares, decreasing 4.27% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 735.00 shares of this stock.
Regeneron Pharmaceuticals Inc News
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regeneron Pharmaceuticals Inc Info
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEOSchleifer (Leonard S)
Websitehttps://www.regeneron.com/
FAQs
What is the current price of Regeneron Pharmaceuticals Inc (REGN)?
The current price of Regeneron Pharmaceuticals Inc (REGN) is 741.290.
What is the symbol of Regeneron Pharmaceuticals Inc?
The ticker symbol of Regeneron Pharmaceuticals Inc is REGN.
What is the 52-week high of Regeneron Pharmaceuticals Inc?
The 52-week high of Regeneron Pharmaceuticals Inc is 790.980.
What is the 52-week low of Regeneron Pharmaceuticals Inc?
The 52-week low of Regeneron Pharmaceuticals Inc is 476.487.
What is the market capitalization of Regeneron Pharmaceuticals Inc?
The market capitalization of Regeneron Pharmaceuticals Inc is 78.06B.
What is the net income of Regeneron Pharmaceuticals Inc?
The net income of Regeneron Pharmaceuticals Inc is 4.41B.
Is Regeneron Pharmaceuticals Inc (REGN) currently rated as Buy, Hold, or Sell?
According to analysts, Regeneron Pharmaceuticals Inc (REGN) has an overall rating of Buy, with a price target of 780.402.
What is the Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN)?
The Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN) is 43.362.
Related Instruments
+1.83%
+0.76%
-0.31%
-0.51%
+0.15%
+1.33%
+0.11%
-0.23%
-2.28%
+0.23%
-0.37%
+1.37%
+2.40%
-0.23%
-0.16%
-0.73%
0.00%
-1.30%
-3.65%Popular Symbols
